COMPANY PROFILE

Grit Science

Explore full profile

Biotechnology firm developing medicine and genetic treatments

ChinaFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Grit Science

Grit Science is a biotechnology company focused on the research and development of biopharmaceutical technology to address clinical needs. Founded in 2018 and headquartered in Beijing, China, the firm develops medical products and genetic treatments.

The company operates as a private entity and has secured investments from notable firms including China Renaissance, Tencent Holdings, and Tsing Song Capital. In 2019, Grit Science established a subsidiary named Huayi Lejian, also based in Beijing.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: China
Open positions: None listed
Dealroom signal: 17.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Mar 2022	$30M	$120M	HSG	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
FIFibroBiologicsDeveloping therapies using fibroblasts, which are a type of cell that is found in connective tissue	Houston, United States	Operational
OBOcelot BioBiotech & Life Sciences	San Diego, United States	Operational
1T101 TherapeuticsDeveloping the first targeted glucocorticoid with all of the potency of steroids but none of the systemic toxicities	Tel Aviv-Yafo, Israel	Operational
CICianatxInnovative therapies for Diabetic Retinopathy, preventing vision loss and blindness with novel treatments	Annapolis, United States	Operational
APAculys PharmaCommitted to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease	Fujisawa, Japan	Acquired
BIBiofronteraSpecializing in dermatological products commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics	Woburn, United States	Operational
EBEucure BiopharmaInnovative immuno-oncology targeted antibodies advancing through clinical trials	Guangzhou, China	Operational